CYAD-211

Overview

CYAD-211 is an allogeneic (donor) CAR T Cell therapy that targets the B-cell maturation antigen (BCMA) chimeric antigen receptor.

SparkCures ID 389
Developed By Celyad Therapeutics
Generic Name CYAD-211
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources